Meta and Google Ad Policy Changes for Healthcare in 2026: Pharma Authorization, AI Ads, and What Got Restricted

Account restriction is not a marketing problem. It is an operating problem.

A restricted Meta or Google ad account is not a policy speed bump. For most DTC telehealth brands, paid is the primary acquisition channel. A restriction shuts off new patient starts within hours, and reinstatement can take weeks or never happen at all.

In 2026, both platforms quietly tightened the rules for healthcare advertising. The official policy pages list the changes. The pattern is consistent: more pharma authorization, less AI-generated medical content, stricter weight loss visuals, and tougher enforcement on affiliate and creator ads.

The brands that did not get restricted are the brands that audited proactively. The brands that did get restricted thought their old creative still complied.

This post is the practical cleanup. What changed, what to remove, what to relabel, and what to do this week if you cannot risk a restriction.

What Meta actually changed in 2026

Meta's pharmaceutical and drug advertising policy was already detailed. The 2026 updates pulled several previously informal rules into formal policy and added new ones.

Expanded pharmaceutical authorization requirements

The Pharmacy and Drug authorization process now applies to a broader set of advertisers, including:

Compounded medication advertisers
Telehealth platforms that prescribe or dispense controlled or scheduled substances
Online pharmacies, including those operating under cross-border arrangements
Some weight loss and GLP-1 advertisers that previously fell into broader categories

If your brand is not currently authorized and you advertise any prescription or controlled substance, including compounded GLP-1s, the platform will increasingly require formal authorization before approving new ads. Operating in the gray area between "wellness" and "prescription" is no longer working.

Stricter rules on AI-generated medical content

Meta added explicit restrictions on AI-generated content in healthcare advertising, including:

AI-generated images of medical conditions, body shapes, or outcomes
AI-generated or deepfake-style celebrity or expert endorsements
AI-rewritten or fabricated testimonials presented as authentic
AI-generated comparisons of medical products

This is a significant change. Previously, AI-generated medical visuals were policed under general advertising standards. They are now a named, restricted category for healthcare.

Tighter rules on weight loss imagery

Body-focused weight loss creative continues to be restricted, but enforcement has tightened around:

Before-and-after imagery with implausible timeframes
Imagery focused on body parts or specific physical features
Weight loss numbers in headlines or imagery
Targeting users under 18

Disclosure requirements for telehealth

The platform now requires more explicit disclosure of:

Prescriber relationships, particularly for telehealth services that include medication prescribing
The nature of compounded versus FDA-approved products
Subscription, renewal, and refund terms in landing-page experience
Affiliate and creator compensation

Stronger enforcement on affiliate and creator content

Brands are increasingly held accountable for affiliate and creator ads run on their behalf. Affiliate-run creatives that violate policy can trigger restriction on the brand account, even when the brand did not create the asset.

For the broader connection to creator program risk, see Affiliate and Creator Programs for DTC Telehealth.

What Google changed in parallel

Google's healthcare advertising policy moved in the same direction in 2026, with some differences.

Expanded pharmacy and medical content authorization

Google's certification process for healthcare advertising has been expanded to cover:

More telehealth categories, particularly weight loss and mental health
Compounded medications as a distinct certification track
Online pharmacy certification with stricter cross-state and cross-border requirements

Restricted AI-generated and synthetic medical content

Google now treats AI-generated medical imagery and synthetic endorsements as restricted under several policies, including its Manipulated Media and Misleading Representation rules. Healthcare-specific enforcement has tightened around the same patterns Meta is restricting.

Tighter rules on health claims in Search and Display

Search ad copy and Display creative now go through tighter review for claims about:

Weight loss amounts and timeframes
Specific medical outcomes
Implied medical endorsements
Comparative claims against branded drugs

Restrictions on certain controlled-substance terms

Search advertising on certain terms tied to controlled-substance acquisition or marketing has tightened. This affects keyword strategy for ADHD, low T, and other controlled-substance programs.

For the related operational view on controlled-substance programs, see DEA Telehealth Controlled-Substance Flexibilities Extended Through 2026.

What this means for your current creative

Walking the policy changes against a typical DTC telehealth ad library, here are the patterns to look for.

Creative pattern	2025 status	2026 status
AI-generated outcome imagery	Tolerated with caveats	Restricted, often disallowed
Deepfake-style celebrity endorsement	Already prohibited	More aggressively enforced
AI-rewritten testimonial presented as real	Risky	Explicit policy violation
Body-focused weight loss imagery	Restricted	Restricted with tighter enforcement
Before-and-after photos with weight numbers	Risky	More likely to be rejected
Compounded GLP-1 without authorization	Tolerated in gray zone	Pushed toward formal authorization
Unbranded GLP-1 wellness creative	Tolerated	Increasingly flagged when product link is prescription
Affiliate creative without brand approval	Brand often deflected risk	Brand bears policy risk directly
Telehealth without prescriber disclosure	Often allowed	Disclosure now expected
Renewal and refund terms buried	Often allowed	Landing-page experience reviewed more closely

If your active library has any of the right-column items, you have policy exposure right now.

The cleanup checklist for this week

Treat this as a single-sprint clean-up plan. Most brands can do this in 5 to 10 working days.

Inventory

Pull a complete list of active creative across Meta, Google, TikTok, and any other paid channels
Include affiliate and creator ads run on the brand's behalf
Tag each asset by category (claim type, imagery type, AI involvement)

AI-asset triage

Identify every asset with AI-generated or AI-modified content
Remove all AI-generated outcome, body, or medical-condition imagery
Remove all AI-generated celebrity or expert endorsements
Remove or label AI-generated b-roll, backgrounds, and stylized assets where they could be mistaken for clinical content
Document remaining AI assets with provenance for audit

Testimonials and endorsements

Verify every quoted patient is real and contactable
Confirm written authorization on file for every endorsement
Add or confirm relationship disclosure (paid, free product, employee)
Remove any quoted testimonial that has been rewritten by AI or staff beyond minor formatting

Weight loss imagery

Pause body-focused close-ups
Replace before-and-after imagery that emphasizes weight numbers or implausible timeframes
Confirm patient written authorization for every remaining before-and-after

Authorization status

Confirm pharmacy and drug authorization status on Meta
Confirm healthcare and pharmacy certification on Google
Initiate authorization for any category currently operating in a gray zone

Landing-page experience

Audit landing pages for clear pricing, subscription terms, renewal terms, and refund policy
Verify prescriber and compounded-versus-FDA-approved disclosures
Verify that ad copy claims match landing page claims

Affiliate and creator

Send updated creative guidelines to all affiliates and creators
Require pre-approval for new creative before it runs
Audit affiliate ad libraries (where available) for non-compliant active assets
Pause affiliates that cannot meet the updated standards

Documentation

Record every cleanup action with date, asset, and owner
Maintain an exportable record in case of platform inquiry

For the broader marketing operations framework, see Marketing Your GLP-1 Program in 2026 and Running GLP-1 Ads in 2026.

Pharmacy and drug authorization, in practice

The authorization process is more involved than it used to be, and it now matters more.

Meta's Pharmacy and Drug authorization generally requires:

A formal application identifying the entity, its registrations, and its scope
LegitScript certification or equivalent for online pharmacies, where applicable
Documentation of prescriber and pharmacy registrations
Specific country-level scope (US authorization is the most relevant for DTC US brands)

Google's certifications for healthcare and pharmacy similarly require:

LegitScript certification for online pharmacies
Specific certification for restricted categories (mental health treatment, addiction services, online pharmacy)
Documentation of state-level registrations where applicable

The brands that struggle here are the ones whose corporate structure does not match their advertising surface. If the LLC that runs the ads is not the same LLC that holds the pharmacy registration, expect friction. Resolving that takes weeks, and it cannot happen mid-restriction.

A clean entity map is a precondition. So is honest internal answers about which programs require which certifications.

What still works (and how to lean into it)

The cleanup is real, but it does not mean creative is dead. The patterns that still perform and stay compliant.

Education-first creative

Long-form copy explaining the program, the process, and the clinical rationale. Performs well, passes review, builds trust.

Real patient stories, properly documented

Authorized, real patient testimonials with proper disclosure are still allowed. They actually perform better when they are clearly authentic.

Mechanism-of-action and clinical-context creative

Explaining how a drug or program works, citing real evidence, is permissible and increasingly differentiated.

Brand voice and team-led creative

Founder and clinical-team-led video that explains the program is generally policy-safe and continues to perform on Meta and YouTube.

Trust-signal creative

Licensing, board certifications, accreditations, security and privacy practices, partner pharmacies, and credible publications featuring the brand. See Trust Signals on Telehealth Landing Pages for the landing-page layer of the same pattern.

The general direction: less synthetic, more authentic, more substantive. The platforms are pushing in this direction and so are state regulators and the FTC. There is now alignment across the layers in what good healthcare creative looks like.

For the related state regulatory layer, see State AG Enforcement on AI Health Ads: What CT, NY, and CA Cases Mean for Telehealth Marketing.

What to monitor weekly

Once the cleanup is done, the standing operating rhythm matters.

Ad-account health

Account-level policy strikes and restrictions
Asset-level rejections by category and platform
Spend caps imposed by platform review

Platform policy updates

Meta's Business Help Center and Pharmaceutical and Drug Policy pages
Google's healthcare and Restricted Content policy updates
TikTok's healthcare advertising policy updates

Affiliate ad libraries

Sample affiliate ad libraries weekly to catch off-spec creative early
Use the Meta Ad Library and Google Ads Transparency Center for sampling

Internal metrics that hint at platform risk

Click-to-landing-page bounce rate (high bounce signals possible review)
Conversion-to-completion drop (signals friction or quality issues)
Spike in support contacts about a specific ad (signals possible policy issue)

A weekly five-minute review catches most issues before they become restrictions.

Final takeaways

The 2026 policy tightening is real, and it is structural, not a phase.

What to remember:

Meta and Google have moved in the same direction: more authorization, less AI-generated medical content, stricter weight loss imagery, tougher enforcement
Brands are now responsible for affiliate and creator creative on the brand account
AI-generated outcome imagery, deepfake endorsements, and AI-rewritten testimonials are the cleanest violations
Pharmacy and drug authorization is no longer optional for many telehealth categories
A clean entity map is a precondition for authorization
Education-first, real-patient, mechanism-of-action, founder-led, and trust-signal creative continues to work
A cleanup sprint plus a weekly monitoring rhythm prevents most restrictions
The platforms, the state AGs, and the FTC are pushing in the same direction: less synthetic, more substantive, more honest

The brands that built ads on a foundation of authentic voice and verifiable claims will find the 2026 environment easier, not harder. The brands that depended on AI shortcuts to fake authenticity are running out of room.

Cleanup now, or restriction later. There is not a third option.

Sources for the policy and platform references: